Abstract
Dyslipidemia (DLD) is a metabolic derangement causing a persistent elevation in plasma cholesterol and/or triglycerides. The three manifestations of dyslipidemia are hypercholesterolemia, hypertriglyceridemia, and mixed hyperlipidemia. It is crucial to screen, diagnose, and treat dyslipidemia in the general population due to the high attributable risk for cardiovascular disease. Dyslipidemia increases atherosclerosis and ASCVD risk by accelerating the atherogenic process. Statin therapies have a substantial benefit in the primary and secondary prevention of ASCVD, and recent evidence reveals that this benefit far outweighs potential risks.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Abbreviations
- ApoB:
-
Apolipoprotein B
- ASCVD:
-
Atherosclerotic cardiovascular disease
- CKD:
-
Chronic kidney disease
- DLD:
-
Dyslipidemia
- FH:
-
Familial hypercholesterolemia
- HDL-C:
-
High-density lipoprotein-cholesterol
- LDL-C:
-
Low-density lipoprotein-cholesterol
- Lp(a):
-
Lipoprotein(a)
- SAMS:
-
Statin-associated muscle symptoms
- TC:
-
Total cholesterol
- TG:
-
Triglycerides
References
Adhyaru BB, Jacobson TA. Safety and efficacy of statin therapy. Nat Rev Cardiol. 2018;15(12):757–69. https://doi.org/10.1038/s41569-018-0098-5.
Jacobson TA, Maki KC, Orringer CE, Jones PH, Kris-Etherton P, Sikand G, et al. National lipid association recommendations for patient-centered management of dyslipidemia: part 2. J Clin Lipidol. 2015;9(6 Suppl):S1–122.e1. https://doi.org/10.1016/j.jacl.2015.09.002.
Wilson DP, Jacobson TA, Jones PH, Koschinsky ML, McNeal CJ, Nordestgaard BG, et al. Use of lipoprotein(a) in clinical practice: a biomarker whose time has come. A scientific statement from the National Lipid Association. J Clin Lipidol. 2019;13(3):374–92. https://doi.org/10.1016/j.jacl.2019.04.010.
Fredrickson DS. An international classification of hyperlipidemias and hyperlipoproteinemias. Ann Intern Med. 1971;75(3):471–2. https://doi.org/10.7326/0003-4819-75-3-471.
Nordestgaard BG, Chapman MJ, Humphries SE, Ginsberg HN, Masana L, Descamps OS, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J. 2013;34(45):3478–90a. https://doi.org/10.1093/eurheartj/eht273.
Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP, et al. Heart disease and stroke statistics-2019 update: a report from the American heart association. Circulation. 2019;139(10):e56–e528. https://doi.org/10.1161/CIR.0000000000000659.
Goldberg AC, Hopkins PN, Toth PP, Ballantyne CM, Rader DJ, Robinson JG, et al. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol. 2011;5(3 Suppl):S1–8. https://doi.org/10.1016/j.jacl.2011.04.003.
Expert Panel on Detection Ea, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA. 2001;285(19):2486–97. https://doi.org/10.1001/jama.285.19.2486.
Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;73(24):3168–209. https://doi.org/10.1016/j.jacc.2018.11.002.
Jialal I, Devaraj S. AHA/ACC/Multisociety cholesterol guidelines: highlights. Ther Adv Cardiovasc Dis. 2019;13:1753944719881579. https://doi.org/10.1177/1753944719881579.
Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019;380(1):11–22. https://doi.org/10.1056/NEJMoa1812792.
Group KDOQIKD. K/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease. Am J Kidney Dis. 2003;41(4 Suppl 3):I–IV, S1-91.
Jacobson TA, Ito MK, Maki KC, Orringer CE, Bays HE, Jones PH, et al. National lipid association recommendations for patient-centered management of dyslipidemia: part 1--full report. J Clin Lipidol. 2015;9(2):129–69. https://doi.org/10.1016/j.jacl.2015.02.003.
Agarwala A, Shapiro MD. Emerging strategies for the management of atherogenic dyslipidaemia. Eur Cardiol. 2020;15:1–3. https://doi.org/10.15420/ecr.2019.16.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Thobani, A., Wenger, N.K. (2022). Dyslipidemia. In: Bhargava, A.A., Wells, B.J., Quintero, P.A. (eds) Handbook of Outpatient Cardiology . Springer, Cham. https://doi.org/10.1007/978-3-030-88953-1_11
Download citation
DOI: https://doi.org/10.1007/978-3-030-88953-1_11
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-88952-4
Online ISBN: 978-3-030-88953-1
eBook Packages: MedicineMedicine (R0)